Home › Kanser sa Prostate › Texas › Dallas
Pag-aaral pangklinika para sa Kanser sa Prostate sa Dallas, TX
36 pag-aaral para sa Kanser sa Prostate ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Dallas (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Nagre-recruitPhase 3
- Urology Clinics Of North Texas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
- UT Southwest Simmons Cancer Center, Dallas
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Nagre-recruitPhase 3
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Nagre-recruitPhase 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Dallas
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Nagre-recruitPhase 3
- Texas Oncology - DFW ( Site 8001), Dallas
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Nagre-recruitPhase 3
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital, Dallas
- University of Texas Southwestern Simmons Cancer Center - Redbird, Dallas
- at 2 pa
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Nagre-recruitPhase 2/3
- Texas Oncology, Dallas
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Nagre-recruitPhase 1
- Mary Crowley Cancer Research, Dallas
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- Texas Oncology - DFW (Sammons CC), Dallas
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 3
- University of Texas Southwestern Medical Center, Dallas
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Nagre-recruitPhase 3
- Parkland Health & Hospital System ( Site 0069), Dallas
- UT Southwestern Medical Center ( Site 0039), Dallas
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Nagre-recruitPhase 3
- Urology Clinics of North Texas, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
- SCRI at Mary Crowley, Dallas
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Nagre-recruitPhase 2
- University of Texas Southwestern Medical Center, Dallas
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Nagre-recruitPhase 1/2
- University of Texas Southwestern Medical Center, Dallas
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Nagre-recruitPhase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Nagre-recruitPhase 2
- University of Texas Southwestern Medical Center, Dallas
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Nagre-recruitPhase 1
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Nagre-recruitPhase 3
- Dallas VA Medical Center, Dallas
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Nagre-recruitPhase 1
- Urology Clinics of North Texas, Dallas
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
Nagre-recruitPhase 2
- UT Southwestern Medical Center-Dallas, Dallas
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Nagre-recruitPhase 3
- UT Southwestern Medical Center, Dallas
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Nagre-recruitPhase 4
- Univ of Texas Southwest Med Center, Dallas
Outcomes of Focal Ablation for Prostate Cancer
Nagre-recruitObservasyonal na pag-aaral
- UTSW, Dallas
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Nagre-recruitPhase 3
- UT Southwestern Medical Center, Dallas
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Nagre-recruitPhase 1/2
- Research Site, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Nagre-recruitPhase 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Nagre-recruitPhase 1
- Urology Clinics of North Texas, Dallas
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Nagre-recruitPhase 4
- UT Southwestern Medical Center, Dallas
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
Nagre-recruitObservasyonal na pag-aaral
- Ut Southwestern Medical Center, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Dallas
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Nagre-recruitPhase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Customized TULSA-PRO Ablation Registry
Nagre-recruitObservasyonal na pag-aaral
- University of Texas Southwestern Medical Center, Dallas
Pag-aaral para sa Kanser sa Prostate sa ibang lungsod
- New York City, NY103 pag-aaral
- Houston, TX76 pag-aaral
- Los Angeles, CA61 pag-aaral
- Boston, MA59 pag-aaral
- St. Louis, MO46 pag-aaral
- Chicago, IL45 pag-aaral
- San Francisco, CA45 pag-aaral
- Philadelphia, PA44 pag-aaral
- Baltimore, MD43 pag-aaral
- Nashville, TN43 pag-aaral
- Seattle, WA42 pag-aaral
- Washington, DC38 pag-aaral
Iba pang pag-aaral sa Dallas
- Kanser sa Suso55 pag-aaral
- Non-Small Cell Lung Cancer52 pag-aaral
- Metastatic Cancer42 pag-aaral
- Pagkabigo ng Puso42 pag-aaral
- Kanser (lahat ng uri)37 pag-aaral
- Colorectal Cancer33 pag-aaral
- Obesity30 pag-aaral
- Kanser sa Ovary28 pag-aaral
- Kanser sa Baga27 pag-aaral
- Kanser sa Pantog27 pag-aaral
- Kanser ng Endometrium24 pag-aaral
- Kanser sa Bato (Renal Cell Carcinoma)23 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.